HC Wainwright Brokers Lower Earnings Estimates for APLS

Key Points

• HC Wainwright has revised its Q3 2025 EPS estimates for Apellis Pharmaceuticals down to ($0.58) from ($0.52), now projecting full-year earnings of ($1.70) per share.
• Despite negative financial indicators, several analysts, including Citigroup and Royal Bank Of Canada, have increased their price targets for APLS, indicating a mixed outlook on the stock.
• Insiders at Apellis Pharmaceuticals have sold a significant amount of shares recently, with CEO Cedric Francois reducing his holdings by 32.84%, raising concerns about insider confidence.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at HC Wainwright decreased their Q3 2025 EPS estimates for Apellis Pharmaceuticals in a report released on Monday, September 29th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.58) for the quarter, down from their previous forecast of ($0.52). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals' Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at ($2.21) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.11. The firm had revenue of $171.39 million during the quarter, compared to the consensus estimate of $187.91 million. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The company's revenue was down 10.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.30) earnings per share.

A number of other equities analysts have also commented on the stock. Royal Bank Of Canada raised their price objective on shares of Apellis Pharmaceuticals from $17.00 to $19.00 and gave the company a "sector perform" rating in a research report on Friday, August 1st. Citigroup upped their target price on shares of Apellis Pharmaceuticals from $41.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Robert W. Baird upped their target price on shares of Apellis Pharmaceuticals from $47.00 to $50.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Wall Street Zen raised shares of Apellis Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd. Finally, Cantor Fitzgerald upped their target price on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $33.29.

Apellis Pharmaceuticals Price Performance

APLS opened at $22.63 on Wednesday. The company has a market capitalization of $2.86 billion, a price-to-earnings ratio of -12.43 and a beta of 0.73. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90. The firm has a 50-day moving average price of $24.70 and a 200-day moving average price of $21.13. Apellis Pharmaceuticals has a twelve month low of $16.10 and a twelve month high of $35.72.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. boosted its stake in shares of Apellis Pharmaceuticals by 0.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 58,856 shares of the company's stock valued at $1,019,000 after purchasing an additional 465 shares in the last quarter. GF Fund Management CO. LTD. boosted its stake in shares of Apellis Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock valued at $70,000 after purchasing an additional 573 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Apellis Pharmaceuticals by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company's stock valued at $84,000 after buying an additional 655 shares during the last quarter. Parallel Advisors LLC raised its holdings in Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock valued at $33,000 after buying an additional 855 shares during the last quarter. Finally, Baird Financial Group Inc. raised its holdings in Apellis Pharmaceuticals by 1.6% during the 1st quarter. Baird Financial Group Inc. now owns 55,529 shares of the company's stock valued at $1,214,000 after buying an additional 864 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 31,092 shares of the business's stock in a transaction that occurred on Friday, September 19th. The shares were sold at an average price of $22.95, for a total value of $713,561.40. Following the completion of the transaction, the director owned 68,908 shares of the company's stock, valued at $1,581,438.60. The trade was a 31.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Cedric Francois sold 175,037 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $28.19, for a total transaction of $4,934,293.03. Following the completion of the transaction, the chief executive officer directly owned 357,909 shares of the company's stock, valued at approximately $10,089,454.71. This represents a 32.84% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 430,919 shares of company stock valued at $10,656,945 in the last quarter. Corporate insiders own 6.80% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.